Ambulatory surgery encompasses the majority of surgical procedures performed in the United States. The number of procedures performed on an ambulatory basis has increased owing to improvements in surgical technology, anesthetic techniques, and pharmacology-specifically analgesic agents. The latter is important as there is an increasing trend of performing more painful procedures on an outpatient basis. 1 Inadequate management of pain or side effects from medications (such as opioids) can lead to decreased patient satisfaction and delayed discharge. Multimodal analgesia captures the effectiveness of individual agents in optimal dosages that maximize efficacy and minimize side effects. This important concept includes the theory that agents with different mechanisms of analgesia 2 may have synergistic effects in preventing or treating pain. Joshi offered guidelines on constructing a multimodal analgesia strategy that, in addition to regional or local anesthesia, included scheduled administration of nonopioid analgesics [eg, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), or cyclooxygenase (COX)-2 inhibitors] using oral opioids only for breakthrough pain. 1 Successful regimens for outpatient (and inpatient) procedures have since been proposed that follow these principles. 3, 4 These regimens must be tailored to individual patients, keeping in mind the procedure being performed, side effects of individual medications, and patients' preexisting medical conditions. ' 
Aniline Derivatives
In 2005, Joshi commented on the underuse of acetaminophen in the perioperative period. 1 Aniline derivatives have mild analgesic, antiinflammatory, and antipyretic properties. The use of these compounds in ambulatory surgery has gained interest of late owing to the development of intravenous formulations (just approved in the United States) and the favorable side effect profiles.
Paracetamol, the intravenous equivalent of acetaminophen, became available in 2002 and provides more predictable bioavailability and predictable onset compared with enteral routes of administration. 5 It has been researched for its ability to spare postoperative opioid use and consequently decrease nausea, vomiting, and sedation. Concern still exists for hepatotoxicity associated with aniline derivatives. A prospective study by Gorocs et al 6 demonstrated the safety and efficacy of preoperative paracetamol when given alone or with other systemic analgesics. One randomized control trial of paracetamol as monotherapy demonstrated the benefits of decreased pain scores, total morphine dose, and nausea postoperatively. 7 Two separate trials failed to validate these results. 8, 9 However, paracetamol appears to confer additional analgesic efficacy when used in various combinations. Intravenous (IV) acetaminophen (OFIRMEV) is the first in the class of IV nonopioid, non-NSAID analgesics available in the United States. The safety and efficacy of IV acetaminophen as a parenteral analgesic agent has a wide array of postoperative settings, from minor outpatient to complicated or major inpatient surgery. It has the potential to provide a significant therapeutic improvement in the treatment of fever and acute postoperative pain. As a combination, NSAIDs and paracetamol decrease pain scores, [10] [11] [12] [13] total opioid consumption, [10] [11] [12] [13] postoperative nausea and vomiting, 10-13 and sedation. 10, 11 Patients expressed greater satisfaction when the combination of NSAIDs and paracetamol was used versus placebo 12 or acetaminophen alone. 10 After segmental mastectomy (with or without axillary lymph node dissection), Ohnesorge et al 8 found that those who received paracetamol in the perioperative period had shorter times to ambulation (around 4 h.)
There appears to be much benefit to incorporating aniline derivatives as part of a multimodal analgesia regimen; as availability of intravenous formulations (such as IV acetaminophen: OFIRMEV) becomes more widespread and anesthesiologists become more comfortable with their administration, their use should increase, which should lead to greater patient satisfaction and improved outcomes from ambulatory surgery. means to prevent and treat postoperative pain in ambulatory surgery. In the past there has been concern regarding nonselective COX inhibitors and side effects that include renal toxicity, gastrointestinal toxicity, platelet inhibition, and exacerbation of asthma. COX-2 inhibitors have gained interest as they spare GI and renal side effects. However, use of COX-2 inhibitors is not without concern; valdecoxib and rofecoxib were withdrawn from use because of serious side effects. Recent research on celecoxib has defined its efficacy 14, 15 and safety.
14 In addition to decreasing pain scores, celecoxib has been associated with decreased opioid consumption, earlier return of bowel function 15 and physical activity, 14 and increased patient satisfaction. Time to discharge was decreased in groups that received ketorolac (P<0.05) for ambulatory anorectal procedures. 16 With regard to timing of dosing, Sun et al 14 showed there is no difference if celecoxib is given before or after surgery.
Newer formulations of ketorolac include an intranasal (IN) spray. Compared with placebo, patients receiving IN ketorolac had improved pain scores in third molar extraction with bony impaction surgery. 17 A randomized controlled trial in patients after abdominal surgery showed 26% less morphine consumed in the first 48 hours postoperative. 18 Both studies remarked on the rapid onset of analgesia, which lasted up to 8 hours, 17 and suggested its benefit in ambulatory or fast-track surgery. 18 The rapid onset and improved analgesia seen with IN ketorolac may be due to higher penetration via the cribriform plate and into the cerebrospinal fluid. Higher cerebrospinal fluid levels of NSAIDs have been associated with greater analgesia. Local injection of ketorolac mixed with lidocaine and bupivacaine mixture was first studied for ambulatory anorectal surgery in 2000 and has not been widely used, despite oral analgesic-sparing properties, improved quality of recovery, and no untoward effects on postoperative bleeding in 1 study. 16 The local application of NSAIDs may prevent some of the systemic side effects seen with administration of these drugs via the oral or injectable route. For patient populations able to tolerate NSAIDs, incorporating them as an oral adjunct has proven to be effective and safe. Local injection or IN formulations appear to have properties that make them suitable for further investigation in ambulatory surgery analgesia regimens.
'

Steroids
Preoperative administration of glucocorticoids attenuates peripheral inflammatory pathways and has been shown to decrease postoperative pain for minor surgical procedures. 3 Concern regarding side effects of steroid administration, such as gastrointestinal or wound complications, has limited widespread use.
In a randomized controlled trial by Coloma et al, 20 4 mg dexamethasone administered preoperatively reduced time to discharge with no increase in wound infections. Preoperative or intraoperative administration of glucocorticoids seems to be sufficient timing to obtain the antiinflammatory benefits. The onset of dexamethasone seems to be rapid with duration of action of 24 to 48 hours. 19 When Kjetil and colleagues 21 added dexamethasone 16 mg to a multimodal analgesia regimen (including paracetamol and COX-2 inhibitor), a prolonged analgesic effect was observed. However, half that dose of dexamethasone did not demonstrate the same effect in a study by Mathiesen and colleagues. 22 Additional benefits of dexamethasone administration include anti-emetic effects. These properties make it an ideal adjunct for the ambulatory setting. An extensive review by Salerno and Hermann 19 concluded that ''the literature clearly reflects the safety of short-term use of corticosteroids for acute postoperative analgesia in relatively healthy individuals.''
'
Anticonvulsants
The use of anticonvulsants, particularly gamma-aminobutyric acid analogs that bind to the a 2 d subunit of voltage-gated calcium channels, as an adjunct to multimodal regimens has increased in the past decade. Presynaptic voltage-gated calcium channels are unregulated in the dorsal root ganglia and spinal cord after surgical trauma, which leads to central sensitization. 23 Some studies have indicated that the use of anticonvulsants decreases the incidence of opioid-related side effects (nausea, vomiting, and pruritis) and increases the incidence of sedation, 24, 25 whereas other studies have been inconclusive. 26 A meta-analysis by Ho and colleagues 24 concluded that a single preoperative dose of gabapentin, 1200 mg or less, reduces pain scores and opioid consumption in the first 24 hours postoperatively. Half that dose, gabapentin 600 mg, given 2 hours preoperatively was effective in reducing pain scores and tramadol consumption by 33% after mini-laparotomy open cholecystectomy in the same time frame; however, pain scores and tramadol consumption returned to similar levels on postoperative day 2. 27 Continuing administration of gabapentin, in addition to a single preoperative dose, appears to have benefit; when given 4 days postoperatively, opioid consumption and some opioid-related side effects were reduced after total knee arthroplasty. 28 Of note, gabapentin has been studied in the pediatric population and a single preoperative dose had similar effects to those seen in the adult population, that being lower pain scores and decreased opioid consumption postoperatively. 29 Pregabalin has been shown to demonstrate a more favorable pharmacokinetic profile than gabapentin, including increased bioavailability, longer half-life, and increased potency. 30, 31 A single dose of pregabalin 150 mg demonstrates similar efficacy to gabapentin in reducing postoperative pain and opioid consumption. 27 A 50% reduction in 24-hour morphine consumption and decreased nausea and vomiting was observed after a 1-time dose of pregabalin 300 mg in patients undergoing total hip arthroplasty. 22 Buvanendran and colleagues 25 demonstrated pregabalin (300 mg 1-time dose followed by 150 mg twice a day) administered in the perioperative period not only decreases the development of chronic pain, but improves surgical outcome as demonstrated with greater range on motion after total knee arthroplasty. Clarke and colleagues 28 had similar findings, along with improved range of motion after total knee arthroplasty, with a shorter course of postoperative gabapentin. Other studies with single doses of pregabalin (75 mg or 150 mg) have shown improved immediate postoperative analgesia, without opioid-sparing effects. 32 Precise dosing of pregabalin is undetermined, as higher doses of pregabalin (600 mg), though effective in decreasing postoperative opioid consumption, are associated with increased incidence of dizziness, blurred vision, and headache. 33 This dose-related increase in side effects was also observed by White and colleagues, 34 though without analgesic benefit. Lower doses of pregabalin, although with lower incidence of side effects, did not show any analgesic benefit after laparoscopic cholecystectomy (50 mg), 35 or minor gynecologic procedures (100 mg.) 36 Pregabalin 150 mg, acetaminophen, and celecoxib administered as a multimodal regimen decreased intraoperative and postoperative opioid use in patients undergoing robotic-assisted laparoscopic prostatectomy without an increase in somnolence or dizziness. 37 A randomized controlled trial by Sen et al, 38 including gabapentin (1200 mg single dose preoperatively) plus intraoperative ketamine infusion, resulted in decreased pain scores, opioid consumption, and decreased chronic pain after total abdominal hysterectomy.
Incorporating anticonvulsants in a multimodal regimen seems to offer not only short-term benefits but long-term effects, such as decreased chronic pain and improved functional outcomes, when continued throughout the immediate postoperative period for certain surgical procedures such as orthopedic surgery. Although some of the studies cited in this section involve inpatient surgical procedures, these same principles can be applied to procedures performed in an outpatient setting. Larger clinical trials need to be carried out with this group of drugs to determine if the incidence of chronic pain after surgery can be reduced in the outpatient setting after orthopedic surgery such as carpal tunnel and minor knee scopes. 40 determined that blockade of the NMDA receptor has been shown to reduce pain scores and analgesic requirements beyond the known duration of action of the substances investigated (ketamine or dextromethorphan). The prolonged effect has led to investigation of the interaction between opioids and dextromethorphan. 39 A precise dose of dextromethorphan necessary to potentiate opioid analgesia is yet to be determined. However, Yeh et al 41 demonstrated a single dose of dextromethorphan 40 mg intramuscular before elective colonic surgery decreased the amount of epidural analgesics in the first 24 hours after surgery; that benefit was absent after 24 hours. Ketamine has been used more frequently although side effects such as nausea, vomiting, and delirium are of concern. Intravenous ketamine (0.5 mg/kg as a 1-time bolus) reduced pain scores and rescue analgesia in children undergoing tonsillectomy compared with placebo in a study by Conceiçȃo and colleagues 42 without increased incidence of side effects. Administering ketamine before incision or at the conclusion of surgery had similar effects on postoperative analgesia.
Although an effect has been seen with single intravenous boluses as noted above, there is mixed evidence of perioperative ketamine infusions. Ketamine infusions have been associated with opioid-sparing, 43, 44 improved rehabilitation, 43 and without increased side effects. 44 Other studies demonstrated no effect in reducing pain scores, opioid consumption, or chronic pain in hysterectomy 38 and thoracotomy. 45 Local injection of ketamine (0.5 mg/kg) in the peritonsillar space during tonsillectomy was shown to have equianalgesic effects as an intravenous 1-time dose of ketamine (0.5 mg/kg) during tonsillectomy 46 but concern over possible serious side effects, such as development of pseudoaneurysms, thrombi, or mortality, was voiced by Shah and Preciado. 47 Memantine, a noncompetitive NMDA receptor antagonist, may prove to be the most applicable for ambulatory surgery. Memantine, when orally administered, allows ease of administration postoperatively, is better tolerated, has a longer half-life, and is the most potent clinically available NMDA receptor antagonist. 39 Daily doses of 30 mg memantine decreased phantom pain by up to 80% at 1 month after amputations in a study by Schley and colleagues. This improvement in phantom pain, was not long-lived as the prevalence of phantom pain approached similar rates as those in the control group at 12 months. 48 Although NMDA receptor antagonists have been shown to have a positive effect on postoperative pain in many studies, the appropriate dose and timing is yet to be determined. Joshi 1 and Suzuki 39 have remarked that NMDA receptor antagonists may have a beneficial role as an adjunct in multimodal analgesia. 
Alpha-2 Adrenergic Agonists
Stimulation of the a 2 adrenergic receptors has been known to produce a variety of favorable effects for anesthesiologists, such as analgesia, sedation, and anxiolysis. Clonidine and dexmedetomidine, commonly used a 2 agonists, have enteral, intravenous, and transdermal routes of administration. Side effects of these medications include bradycardia, hypotension, and excessive sedation. In 2005, White remarked that intravenous clonidine was ''apparently ineffective'' in treating postoperative pain. 49, 50 Owing to the aforementioned side effects, clonidine may not be suitable for ambulatory analgesia except in combination with local anesthetics in peripheral nerve blockade 1 ; doses of less than 0.5 mg/kg perineurally are typically not associated with any hemodynamic side effects. However, one must be cautious using clonidine with subarachnoid blocks in the ambulatory setting owing to the concomitant side effects.
Dexmedetomidine is a highly selective a 2 agonist with a short duration of action. Arain and colleagues found that a 4-hour infusion started 30 minutes before the conclusion of surgery was effective in reducing morphine consumption by 66% in the early postoperative period. This was without an increase in sedation, hypotension, or changes in nausea or vomiting. 51 An intraoperative infusion of dexmedetomidine produced reduced volatile anesthetic doses (by 19% to 22%), reduced postoperative opioid needs (by 36% to 42%), decreased nausea and vomiting, and shorter postanesthesia care unit stay in patients undergoing laparoscopic bariatric surgery. Prolonged effects (eg, opioid sparing or shorter hospital stay) were absent, attributable to dexmedetomidine's short half-life. 52 In patients undergoing laparoscopic gynecologic surgery, Salman and colleagues suggested that dexmedetomidine could be used as an alternative for remifentanil in ambulatory surgery, as a constant infusion reduced postoperative analgesic requirements, nausea, and vomiting. The only drawback was a prolonged recovery, including time to extubation. 53 Although dexmedetomidine and clonidine possess many desired effects, current administration practices seem cumbersome for the ambulatory setting. Dexmedetomidine infusions may have benefit in longer, more painful procedures. Further research may provide newer methods or different formulations that address these limitations. Use of a 2 agonists as adjuncts in regional anesthesia should always be considered, as their safety profile and ability to prolong analgesia has been demonstrated. ' 
Beta-Adrenergic Antagonists
The use of b-adrenergic blocking agents as a method of preemptive or preventive analgesia has gained considerable interest in the past 5 years. b-blockers have been associated with blunting the sympathetic response, opioid-sparing effects, and anticatabolic properties, 30 yet the exact mechanism of these effects is unknown. Incision at the beginning of surgery is associated with activation of the sympathetic nervous system; one thought is that the release of catecholamines enhances excitability of hippocampal NMDA receptors, which may play a role in nociception. 54 Another possible mechanism of analgesia is by decreasing hepatic blood flow, thereby decreasing the metabolism of circulating opioids. 30 Pranevicius and Pranevicius hypothesized that patients' pain thresholds remain at a normal level with esmolol infusions, as opposed to intermittent fentanyl or remifentanil infusions that can lead to opioidinduced hyperalgesia and lower pain thresholds. They speculated that the absence of opioid-induced hyperalgesia in turn led to lower postoperative opioid use and faster recovery. 55 Esmolol is a lipophilic, ultra-short acting, b 1 -selective antagonist that has been studied in ambulatory surgery. Intraoperative esmolol boluses followed by short-term infusions have led to opioid sparing intraoperatively 56 and postoperatively. [56] [57] [58] However, this opioid-sparing effect seems to be limited to lasting from as little as 24 hours postoperative 57 to as much as 3 days postoperative. 59 Coloma and colleagues 60 reported this limited effect, noting increased use of hydrocodone after discharge in patients who received esmolol infusions in place of opioids. Despite its limited duration of postoperative analgesia, esmolol is quite effective intraoperatively as it has been used successfully and safely in place of a remifentanil infusion in fast-track anesthesia. 60 It has reliably been associated with decreased postoperative nausea and vomiting, presumably by sparing narcotic use. 56, 57, 60 In addition, esmolol has been reported to decrease time to emergence, 58 and shorten time to discharge from the recovery room. 57, 58 Bilotta et al, 61 were unable to reproduce any of these effects, albeit in patients undergoing craniotomy and using a lower dose of esmolol.
'
Local Anesthetics
Local anesthetics have been found to have multiple mechanism of analgesia, including voltage-gated sodium channel blockade, 62 inhibition of G protein-coupled receptors, 62 antagonism of NMDA receptors, 63 and modulation of the inflammatory response. 64 In an inpatient setting, patients undergoing laparoscopic colectomy, lidocaine bolus followed by 24-hour infusion resulted in anesthetic sparing (35% less volatile anesthetic) and a >50% reduction in intraoperative and postoperative opioids. In addition patients receiving lidocaine infusions had earlier return of bowel function, lower postoperative fatigue, and as a result 1 less day of hospitalization. 65 Similar findings were observed in patients undergoing laparoscopic cholecystectomy; lidocaine bolus followed by infusion for duration of case had anesthetic-sparing and opioid-sparing effects. 66 Other studies have confirmed opioid-sparing effects, 67 earlier return of bowel function, 68 improved ambulation, 67 and shorter hospital stay. 68 The anti-inflammatory effects of lidocaine, with attenuated levels of proinflammatory mediators [interleukin (IL)-6, IL-8, IL-1ra, complement C3a, integrins, and platelet leukocyte aggregates], have been demonstrated by Herroeder et al 68 and Yardeni et al. 69 However, a study on patients undergoing total abdominal hysterectomy showed no difference in postoperative pain scores, a lack of opioid-sparing effect, and similar times to discharge as placebo. 70 McCarthy and colleagues reviewed 16 studies with 764 total patients receiving lidocaine infusions. The dosage of lidocaine included boluses of 100 mg (or 1.5 to 2 mg/kg) followed by infusions of 1.5 to 3 mg/kg/h (or 2 to 3 mg/min.) They determined a clear benefit in abdominal surgery with less postoperative nausea/vomiting, earlier return of bowel function, earlier ambulation and rehabilitation, and shorter hospitalizations. They concluded a ''continuous infusion of perioperative lidocaine has a clear advantage in abdominal surgery.'' Plasma levels of lidocaine during infusions have been measured within a safe (<5 mg/mL) range except in 1 patient who had a level of 5.8 mg/mL after the initial bolus. However, these infusions seem to be safe; there are no reported cases of CNS toxicity in patients undergoing lidocaine infusion. 71 Lidocaine infusions may provide benefit for ambulatory surgery patients as more invasive and extensive abdominal procedures are performed on an outpatient basis. Dosing studies and research regarding the duration of infusions should be a focus of future investigations. 
Intra-articular Analgesia
Ease of administration, efficacy in achieving pain relief, and lack of systemic side effects are reasons intra-articular (IA) analgesia became popular for ambulatory surgery. 72 Procedures in which this has been demonstrated include knee and shoulder arthroscopy. However, for as many studies that demonstrate a positive effect for IA analgesia there seems to be several that demonstrate the contrary. In addition to this, very recent reports of chondrolysis after IA injections and infusions has led to controversy. 73 A variety of substances, including local anesthetics, opioids, NSAIDs, corticosteroids, a 2 agonists, and NMDA receptor antagonists, have been used in IA analgesia as early as 1985. 74 The many variables in IA analgesia include varying pharmacokinetic profiles and dosages of individual agents; this has led to varying efficacy in pain relief and creative combinations of drugs being used. One such combination that has been investigated is a bupivacaine-morphine combination, which demonstrated positive effects on postoperative pain in multiple studies. [75] [76] [77] After completing a systematic review, Kalso and colleagues concluded morphine 5 mg IA seemed to be an optimal dose and could provide as much as 27 hours of analgesia postoperatively. 78 A doserange effect of morphine was confirmed by Gupta et al, 79 also noting that the analgesic effect was ''mild.'' Ketorolac IA has had analgesic properties when compared with low doses of bupivacaine or morphine. 80 Some authors have included ketorolac as part of a combination IA injection; when used with bupivacaine and morphine, ketorolac 60 mg IA led to longer duration of analgesia after arthroscopic knee surgery with more patients well enough to return to work on postoperative days 1 and 2. 81 Addition of a corticosteroid, methylprednisolone 40 mg, to a morphine-bupivacaine injection had a similar ability to further enhance analgesia and allow patients to return to work earlier in a study by Rasmussen and colleagues. 82 Side effects of steroids, such as delayed wound healing or infection, with steroid injections was not observed in a study of 30 patients by Wang et al. 83 In patients undergoing arthroscopic meniscectomy, addition of clonidine 1 mg/kg to a mixture of bupivacaine and morphine injected intra-articularly resulted in significantly prolonged analgesia and less opioid consumption postoperatively. 84 Finally, the use of IA ketamine 0.5 mg/kg was cited in a small study by Dal et al 85 to have analgesic effects when compared with placebo. However, the study also compared ketamine to bupivacaine IA, which had greater analgesic effects as an individual agent.
Timing of IA injection may be important, as well. A single IA injection of morphine followed by another 10 minutes of tourniquet time improved postoperative analgesia in a study by Whitford and colleagues. 86 This too, is controversial as other studies have found no difference with varying tourniquet times, 87 or after the tourniquet was deflated completely. 77 The type of procedure has also been linked to varying effects of IA agents. Patients undergoing knee procedures associated with ''high inflammatory response'' (eg, anterior cruciate ligament reconstruction, lateral release, patellar shaving, and plica removal) had improved analgesia with morphine compared with bupivacaine. This was in contrast to patients undergoing diagnostic arthroscopy or partial meniscectomy (associated with ''low inflammation'') who had better pain control with bupivacaine compared with morphine. 88 Use of regional, neuraxial, or systemic analgesia in addition to IA analgesia has been noted as a possible confounding factor in evaluating efficacy of IA studies. The exact mechanism is currently unknown.
IA analgesia in shoulder surgery has been compared with parenteral analgesics and interscalene brachial plexus blockade (ISB). In patients undergoing arthroscopic acromioplasty, ISB is superior to IA or suprascapular nerve blockade. When compared with controls, only patients receiving ISB had significant reductions in pain scores and morphine consumption in the postanesthesia care unit. 89 To provide longer-lasting analgesia, continuous IA infusions may be necessary. After rotator cuff repair, implantation of an IA catheter with infusion of ropivacaine led to an improvement in pain for 12 hours postoperatively but no change in postoperative opioid consumption. The authors argued that the use of continuous IA infusions were ''not worth the substantial additional costs.'' 90 Similar findings occurred after arthroscopic subacromial decompression with a catheter in the subacromial space: improved pain scores but no change in opioid consumption. 91 Other studies have shown neither a decrease in pain score nor opioid consumption. 92 These findings have led Fredrickson et al, 73 to question the practicality of IA analgesia in the recent times. Earlier studies were conducted on less painful shoulder procedures (arthroscopic, nonrotator cuff) and may be the reason for the discrepancy with contemporary findings.
Chondrolysis is defined as the disappearance of articular cartilage as a result of dissolution of cartilage matrix and chondrocytes in a short period of time leading to severe osteoarthritis and long-term disability; it is considered to be a rare disease of the shoulder. 93 Animal models have recently indicated the chondrotoxicity of bupivacaine in rabbit models. 94 Twenty-three cases of chondrolysis in young patients (aged 15 to 47) who underwent shoulder surgery were reviewed by Bailie and Ellenbecker. 93 Various substances have been investigated for efficacy in relieving postoperative pain in arthroscopic surgery. With contradicting results, it is prudent to consider the variables mentioned here while evaluating individual studies' outcomes. IA injection of opioids and local anesthetics may be safe in the knee. In theory, combinations of agents with differing mechanisms of action may allow for lower doses of individual drugs, while potentiating analgesic effects. Continuous and patient-controlled IA infusions are also discouraged as prolonged exposure to pharmacologic agents may be the trigger for development of chondrolysis. Larger scale studies are necessary to evaluate the benefit of substances other than opioids and local anesthetics. In addition, determining timing and optimum dosages and establishing safety profiles are crucial if IA analgesics are to evolve as a component of multimodal analgesic regimens.
'
Conclusions
The role of ambulatory analgesia has become an important focus of all providers in outpatient surgery. Coordinating a perioperative regimen with the surgeon and recovery room staff will facilitate an expedited, less painful recovery for the patient. By implementing multimodal regimens composed of NSAIDs, acetaminophen, and shortacting opioids, many patients will have improved analgesia after mild-tomoderate painful procedures. The use of steroids, anticonvulsants, and NMDA receptor antagonists should be considered based on the amount of postoperative pain anticipated and coexisting medical diseases. Infusions, such as a 2 agonists, b-blockers, and local anesthetics, may also prove useful in more painful procedures and in surgeries that may be difficult to cover using RA techniques, but are likely to be cumbersome in the fast-paced setting of an outpatient surgery center. To facilitate quicker onset of analgesics, using new routes of administration (eg, IN ketorolac or ketamine) may become increasingly popular. Their use should also be emphasized, as many studies already demonstrate fewer side effects. As advancements in pharmacology and equipment improve, so should the anesthesiologist's ability to provide a safe, balanced, multimodal analgesic regimen for a variety of outpatient surgical procedures.
